Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia

Mauro Michael J.

首页> 外文期刊>Current opinion in hematology >Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia

【24h】

Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia

机译：慢性骨髓白血病反应不足患者的新型酪氨酸激酶抑制剂

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose of review

机译：审查的目的

著录项

来源
《Current opinion in hematology》 |2019年第2期|共5页
作者
Mauro Michael J.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr Leukemia Serv Myeloproliferat Neoplasms Program New York NY 10065;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词
allosteric inhibitor; T315I mutation; tyrosine kinase inhibitor resistance;

机译：变构抑制剂;T315I突变;酪氨酸激酶抑制剂抗性;

相似文献

外文文献
中文文献
专利

1. Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia [J] . Mauro Michael J. Current opinion in hematology . 2019,第2期

机译：慢性骨髓白血病反应不足患者的新型酪氨酸激酶抑制剂
2. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor [J] . Kyoko Inokura, Yasushi Onishi, Kenji Shimosegawa, Annals of Hematology . 2012,第11期

机译：慢性粒细胞白血病患者的费城阴性急性早幼粒细胞白血病，经酪氨酸激酶抑制剂治疗后完全细胞遗传反应
3. Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor [J] . InokuraK., OnishiY., ShimosegawaK., Annals of hematology . 2012,第11期

机译：在用酪氨酸激酶抑制剂治疗后，在慢性骨髓白血病患者患有慢性骨髓白血病的患者中的费城阴性急性早产儿白血病
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. The multi-targeted receptor tyrosine kinase inhibitor, linifanib (ABT-869), induces apoptosis and inhibits proliferation of leukemia cells through phosphoinositide-3 kinase (PI3K)/AKT-dependent signaling pathways. [D] . Hernandez, Jenny Elizabeth. 2010

机译：多靶点受体酪氨酸激酶抑制剂利尼法尼（ABT-869）通过磷酸肌醇3激酶（PI3K）/ AKT依赖性信号传导途径诱导凋亡并抑制白血病细胞的增殖。
6. BCR‐ABL1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors [O] . Hye‐young Song, Hayeon Noh, Soo young Choi, 2018

机译：BCR-ABL1转录水平在4周时对特定时间反应和预测用各种酪氨酸激酶抑制剂治疗的慢性慢性粒细胞白血病患者的生存具有预后意义
7. BCR-ABL1transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors [O] . Hye-young Song, Hayeon Noh, Soo young Choi, 2018

机译：4周的BCR-ABL1Transcript水平对多种酪氨酸激酶抑制剂治疗的慢性相慢性髓性白血病患者预测慢性相慢性骨髓性白血病患者的存活具有预后意义

Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia

摘要

著录项

相似文献

相关主题

期刊订阅